Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Hysterectomy & Lymphadenectomy in Ovarian Tumor Care

Gynecol Oncol; ePub 2017 Jan 25; Matsuo, et al

Both hysterectomy and lymphadenectomy may be omitted in the surgical management of women with stage T1 borderline ovarian tumors (BOTs), especially for those with T1a disease regardless of age, a recent study found. This retrospective study included 4,943 women (mean age 48.7 years; 75.3% had stage T1a disease) from 1988 to 2003 and examined the association of surgery patterns and cause-specific survival (CSS). Researchers found:

  • Median follow-up was 15.6 years and 159 (3.2%) women died of BOTs.
  • Hysterectomy and lymphadenectomy were performed in 1,909 (38.6%) and 1,295 (26.2%) cases, respectively.
  • Surgery patterns differed significantly across age, ethnicity, marital status, year at diagnosis, and tumor size.
  • Neither procedure was associated with survival in stage T1 BOTs.

Citation:

Matsuo K, Machida H, Takiuchi T, et al. Role of hysterectomy and lymphadenectomy in the management of early-stage borderline ovarian tumors. [Published online ahead of print January 25, 2017]. Gynecol Oncol. doi:10.1016/j.ygyno.2017.01.019.